Protective Effects of Jujubosides on 6-OHDA-Induced Neurotoxicity in SH-SY5Y and SK-N-SH Cells

Molecules. 2022 Jun 26;27(13):4106. doi: 10.3390/molecules27134106.

Abstract

6-hydroxydopamine (6-OHDA) is used to induce oxidative damage in neuronal cells, which can serve as an experimental model of Parkinson's disease (PD). Jujuboside A and B confer free radical scavenging effects but have never been examined for their neuroprotective effects, especially in PD; therefore, in this study, we aimed to investigate the feasibility of jujubosides as protectors of neurons against 6-OHDA and the underlying mechanisms. 6-OHDA-induced neurotoxicity in the human neuronal cell lines SH-SY5Y and SK-N-SH, was used to evaluate the protective effects of jujubosides. These findings indicated that jujuboside A and B were both capable of rescuing the 6-OHDA-induced loss of cell viability, activation of apoptosis, elevation of reactive oxygen species, and downregulation of the expression levels of superoxide dismutase, catalase, and glutathione peroxidase. In addition, jujuboside A and B can reverse a 6-OHDA-elevated Bax/Bcl-2 ratio, downregulate phosphorylated PI3K and AKT, and activate caspase-3, -7, and -9. These findings showed that jujubosides were capable of protecting both SH-SY5Y and SK-N-SH neuronal cells from 6-OHDA-induced toxicity via the rebalancing of the redox system, together with the resetting of the PI3K/AKT apoptotic signaling cascade. In conclusion, jujuboside may be a potential drug for PD prevention.

Keywords: 6-hydroxydopamine; Parkinson’s disease; apoptosis; caspase; jujubosides; reactive oxygen species.

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Humans
  • Neuroblastoma* / drug therapy
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Neurotoxicity Syndromes*
  • Oxidopamine / toxicity
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Neuroprotective Agents
  • Reactive Oxygen Species
  • Oxidopamine
  • Proto-Oncogene Proteins c-akt

Grants and funding

This study was supported by grants from China Medical University Hospital (DMR-111-098), Taoyuan General Hospital, Ministry of Health and Welfare (PTH110027), Taichung Armed Forces General Hospital (TCAFGH-D-109024), and China Medical University Hospital and Asia University (CMU110-ASIA-01). The funders had no role in the study design, data collection, statistical analysis, decision to publish, or manuscript preparation.